medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-9-73-79medalphabet-3780Research ArticleСтатьиРетиноид четвертого поколения трифаротен в терапии акне: первый опыт применения в реальной клинической практикеTrifarotene, a retinoid of the fourth generation, in the treatment of acne: the first experience of use in a real clinical practicehttps://orcid.org/0000-0002-5044-5265КругловаЛ. С.KruglovaL. S.

Круглова Лариса Сергеевна - д. м. н., проф., проректор по учебной работе, зав. кафедрой дерматовенерологии и косметологии.

Москва

Larisa S. Kruglova - DM Sci (habil.), professor, vice-rector for academic affairs, head of Dept of Dermatovenereology and Cosmetology.

Moscow

kruglovals@mail.ruhttps://orcid.org/0009-0000-8395-734XМайрансаеваС. Р.MayransaevaS. R.

Майрансаева София Руслановна - ординатор кафедры дерматовенерологии и косметологии.

Москва

Sofia R. Mayransaeva - resident at Dept of Dermatovenerology and Cosmetology.

Moscow

sofia.mairansaeva@gmail.comhttps://orcid.org/0000-0003-3437-5233ГрязеваН. В.GryazevaN. V.

Грязева Наталья Владимировна - к. м. н., врач-дерматовенеролог, доцент кафедры дерматовенерологии и косметологии.

Москва

Natalya V. Gryazeva - PhD Med, dermatovenereologist, associate professor at Dept of Dermatovenereology and Cosmetology.

Moscow

tynrik@yandex.ruФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy of the Administrative Department of the President of RussiaRussian Federation20242107202409Дерматология (1)7379Copyright © Круглова Л.С., Майрансаева С.Р., Грязева Н.В., 20242024Круглова Л.С., Майрансаева С.Р., Грязева Н.В.Kruglova L.S., Mayransaeva S.R., Gryazeva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3780

В статье представлены данные о топическом ретиноиде четвертого поколения трифаротене. Приведены результаты трех крупных международных клинических исследований, доказавших хорошую эффективность и долгосрочную безопасность монотерапии препаратом трифаротен у пациентов с акне умеренной степени тяжести и тяжелой степени в комбинированной терапии. Показано, что трифаротен демонстрирует высокую селективность к рецепторам ретиноевой кислоты RAR-γ, преобладающих в коже, что обеспечивает клиническую эффективность в низкой дозировке (50 мкг/г) и хорошую переносимость.

В статье представлены клинические примеры по использованию трифаротена в лечении больных акне.

The article presents data on the local retinoid of the fourth generation trifarotene. The results of three large trials have been presented, which have proven good efficacy and long-term safety of monotherapy of the drug trifarotene in patients with moderate acne and in patients with severe acne for combination therapy. It has been shown that trifarotene demonstrates high selectivity to retinoic acid receptors RAR-γ, which are predominant in the skin, which provides clinical efficacy in low concentration and good tolerability.

акнетопические ретиноидытрифаротенэффективность и безопасность в лечении акнеacnetopical retinoidstrifaroteneefficacy and safety in acne treatmentReferencesАкне и розацеа. Клинические проявления, диагностика и лечение / Л. С. Круглова, А. Г. Стенько, Н. В. Грязева и др. под ред. Л. С. Кругловой. – Москва: ГЭОТАР-Медиа, 2023. – 208 с. – ISBN 978–5–9704–7755–7, DOI: 10.33029/9704–6063–4-ACN‑2021–1–208.Acne and rosacea. Clinical manifestations, diagnosis and treatment / L. S. Kruglova, A. G. Stenko, N. V. Gryazeva and others, ed. L. S. Kruglova. - Moscow: GEOTAR-Media, 2023. - 208 p. - ISBN 978-5-9704-7755-7, DOI: 10.33029/9704-6063-4-ACN-2021-1-208.Tan J. K., Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015 Jul;172 Suppl 1:3–12. doi: 10.1111/bjd.13462. PMID: 25597339.Tan J. K., Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015 Jul;172 Suppl 1:3–12. doi: 10.1111/bjd.13462. PMID: 25597339.Del Rosso J. Q., et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol 2007; 6(6):597–600.Del Rosso J. Q., et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol 2007; 6(6):597–600.Круглова Л. С., Иконникова Е. В. Результаты открытого сравнительного исследования эффективности и переносимости терапии двумя лекарственными формами адапалена (0,1 % крем и 0,1 % гель) с применением косметических средств и без них при акне легкой и средней степени. Клиническая дерматология и венерология. – 2018.-17(5).-С. 74–78.Kruglova L.S., Ikonnikova E.V. Results of an open comparative study of the effectiveness and tolerability of therapy with two dosage forms of adapalene (0.1% cream and 0.1% gel) with and without the use of cosmetics for mild to moderate acne. Clinical dermatology and venereology. – 2018.-17(5).-S. 74-78.Bhat Y. J., Latief I., Hassan I. Update on etiopathogenesis and treatment of Acne. Indian J Dermatol Venereol Leprol. 2017;83(3):298.Bhat Y. J., Latief I., Hassan I. Update on etiopathogenesis and treatment of Acne. Indian J Dermatol Venereol Leprol. 2017;83(3):298.Jeremy A. H., Holland D. B., Roberts S. G., et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003; 121(1):20–27. doi: 10.1046/j.1523–1747.2003.12321.x.Jeremy A. H., Holland D. B., Roberts S. G., et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003; 121(1):20–27. doi: 10.1046/j.1523–1747.2003.12321.x.Tanghetti EA. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 2013;6(9):27–35.Tanghetti EA. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 2013;6(9):27–35.Tenaud I., Khammari A., Dreno B. In vitro modulation of TLR‑2, CD 1d and IL‑10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500–506. doi: 10.1111/j.1600–0625.2007.00552.x.Tenaud I., Khammari A., Dreno B. In vitro modulation of TLR‑2, CD 1d and IL‑10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500–506. doi: 10.1111/j.1600–0625.2007.00552.x.Liu P. T., Krutzik S. R., Kim J., Modlin R. L. Cutting edge: all-trans retinoic acid down-regulates TLR 2 expression and function. J Immunol. 2005;174(5):2467–2470. doi: 10.4049/jimmunol.174.5.2467.Liu P. T., Krutzik S. R., Kim J., Modlin R. L. Cutting edge: all-trans retinoic acid down-regulates TLR 2 expression and function. J Immunol. 2005;174(5):2467–2470. doi: 10.4049/jimmunol.174.5.2467.Aubert J., Piwnica D., Bertino B., Blanchet-Réthoré S., Carlavan I., Déret S., et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018;179:442–56.Aubert J., Piwnica D., Bertino B., Blanchet-Réthoré S., Carlavan I., Déret S., et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018;179:442–56.Beard R. L., Chandraratna R. A. RAR-selective ligands: Receptor subtype and function selectivity In: Nau H., Blaner W. S., eds. Retinoids: The Biochemical and Molecular Basis of Vitamin A and Retinoid Action. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer; 1999. p.:185–213.Beard R. L., Chandraratna R. A. RAR-selective ligands: Receptor subtype and function selectivity In: Nau H., Blaner W. S., eds. Retinoids: The Biochemical and Molecular Basis of Vitamin A and Retinoid Action. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer; 1999. p.:185–213.Galderma. Galderma trifarotene development program meets key milestone for lamellar ichthyosis orphan disease [media release]; 2016. http://www.galderma.com/. Accessed June 9, 2016.Galderma. Galderma trifarotene development program meets key milestone for lamellar ichthyosis orphan disease [media release]; 2016. http://www.galderma.com/. Accessed June 9, 2016.FDA. Novel drug approvals for 2019; 2019. http://www.fda.gov. Accessed October 15, 2019. 52.FDA. Novel drug approvals for 2019; 2019. http://www.fda.gov. Accessed October 15, 2019. 52.Общая характеристика лекарственного препарата Аклиф. Рег. удостоверение ЛП-№ (001233)-(РГ-RU) от 19.09.2022.General characteristics of the drug Aklif. Reg. certificate LP-No. (001233)-(RG-RU) dated 09.19.2022.Dreno B., Chavda R., Julia V., Khammari A., Blanchet-Réthoré S., Krishnaswamy JK. Transcriptomics analysis indicates trifarotene reverses acne-related gene expression changes. Front Med. 2021;8:745822. doi: 10.3389/fmed.2021.745822.Dreno B., Chavda R., Julia V., Khammari A., Blanchet-Réthoré S., Krishnaswamy JK. Transcriptomics analysis indicates trifarotene reverses acne-related gene expression changes. Front Med. 2021;8:745822. doi: 10.3389/fmed.2021.745822.Chien A. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12): s51–55.Chien A. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12): s51–55.Wagner N., Benkali K., Alio Saenz A., Poncet M., Graeber M. Clinical pharmacology and safety of trifarotene, a first-in-class RARγ-selective topical retinoid. . J Clin Pharmacol. 2020. doi: 10.1002/jcph.1566.Wagner N., Benkali K., Alio Saenz A., Poncet M., Graeber M. Clinical pharmacology and safety of trifarotene, a first-in-class RARγ-selective topical retinoid. . J Clin Pharmacol. 2020. doi: 10.1002/jcph.1566.Tan J., Thiboutot D., Popp G., et al. Randomized Phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699. doi: 10.1016/j.jaad.2019.02.044.Tan J., Thiboutot D., Popp G., et al. Randomized Phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699. doi: 10.1016/j.jaad.2019.02.044.Brumfiel CM, Patel MH, Bell KA, Cardis MA. Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris. Ther Clin Risk Manag. 2021 Jul 26;17:755–763. doi: 10.2147/TCRM.S286953. PMID: 34345173; PMCID: PMC 8324978.Brumfiel CM, Patel MH, Bell KA, Cardis MA. Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris. Ther Clin Risk Manag. 2021 Jul 26;17:755–763. doi: 10.2147/TCRM.S286953. PMID: 34345173; PMCID: PMC 8324978.Blume-Peytavi U, Fowler J, Kemeny L, et al. Long-term safety and efficacy of trifarotene 50 mug/g cream, a first-in-class RAR-gamma selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–173. doi: 10.1111/jdv.15794.Blume-Peytavi U, Fowler J, Kemeny L, et al. Long-term safety and efficacy of trifarotene 50 mug/g cream, a first-in-class RAR-gamma selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–173. doi: 10.1111/jdv.15794.Tan J., et al. The Personalised Acne Care Pathway-Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts. JAAD Int. 2021;18;5:101–111.Tan J., et al. The Personalised Acne Care Pathway-Recommendations to guide longitudinal management from the Personalising Acne: Consensus of Experts. JAAD Int. 2021;18;5:101–111.Del Rosso J. Q., Lain E., York J. P., Alexis A. Trifarotene 0.005 % Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series. Dermatol Ther (Heidelb). 2022 Sep;12(9):2189–2200. doi: 10.1007/s13555–022–00788-w. Epub 2022 Aug 22. PMID: 35994159; PMCID: PMC 9464295.Del Rosso J. Q., Lain E., York J. P., Alexis A. Trifarotene 0.005 % Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series. Dermatol Ther (Heidelb). 2022 Sep;12(9):2189–2200. doi: 10.1007/s13555–022–00788-w. Epub 2022 Aug 22. PMID: 35994159; PMCID: PMC 9464295.

The authors declare that there are no conflicts of interest present.